View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Tenet Healthcare Corp: 1 director

A director at Tenet Healthcare Corp sold 2,178 shares at 197.470USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

Mendus AB: 1 director

A director at Mendus AB bought 55,000 shares at 5.000SEK and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

 PRESS RELEASE

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Inject...

Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or added to a multimodal regimen, recognized as significantly reducing the risk of PONV, and aprepitant monotherapies are noted as more effective compared to ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...

 PRESS RELEASE

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights ...

Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress Generated Q3 2025 Net Revenue of $38.2 million and year-to-date revenue of $114.3 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million and adjusted EBITDA of $9.0 - $13.0 millionZYNRELEF® Net Revenue grew 49% in Q3 2025, as compared to Q3 2024, continuing momentum with the launch of the Vial Access Needle (VAN) and enhanced incentive program with key distributorsAPONVIE® Net Revenue grew 173% in Q3 2025, as compared to Q3 2024, supported by increased adoption and momentum buildi...

Moody's Ratings assigns Ba3 and B2 ratings to Tenet Healthcare's propo...

Moody's Ratings (Moody's) assigned Ba3 rating to Tenet Healthcare Corporation's ("Tenet") proposed offering of senior secured first lien notes due 2032 and B2 rating to the senior unsecured notes proposed offering due 2033. Tenet intends to use the net proceeds from this offering for general corpora...

 PRESS RELEASE

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of ...

Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of Au...

Tenet Healthcare Corporation: Update to credit analysis

Our credit view of this issuer reflects its considerable scale and its very good liquidity and favorable debt maturity profile, offset by its moderately high financial leverage.

Moody's Ratings affirms Tenet Healthcare Corporation's Ba3 CFR; revis...

Moody's Ratings (Moody's) affirmed the ratings of Tenet Healthcare Corporation ("Tenet") including the Ba3 Corporate Family Rating (CFR), Ba3-PD Probability of Default Rating (PDR), Ba3 ratings of senior secured first and second lien notes and B2 rating of senior unsecured notes. At the same time, w...

 PRESS RELEASE

Heron Therapeutics to Report Third Quarter 2025 Financial Results on T...

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following  which will provide participants with dial-in details. To av...

Assured Guaranty Ltd: 1 director

A director at Assured Guaranty Ltd sold 25,000 shares at 83.830USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Expecting a Test of All-Time Highs The market remains relentlessly strong, shrugging off the latest "bearish" headline regarding Moody's U.S. debt downgrade on Friday. This is exactly what we would expect to happen in a bull market, particularly during this "lockout rally," and helps confirm our bullish outlook. To recap, we have been short-term bullish since our 4/22/25 Compass -- when the SPX was testing 5100-5120 support -- but we upgraded our intermediate-term outlook to bullish as well, as...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: March 29, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: December 1, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MCHX MARCHEX INC. CL B
LTRX LANTRONIX INC.
HSII HEIDRICK & STRUGGLES INTERNATIONAL INC.
HASI
I3N HANNON ARMSTRONG SUSTAINABLE INFRASTRUCTURE CAPITAL INC.
EXAS CHART INDUSTRIES INC.
EL EXACT SCIENCES CORPORATION
CROX ESTEE LAUDER COMPANIES INC. CLASS A
CNC CROCS INC.
BRKR CENTENE CORPORATION
APPS BRUKER CORPORATION
AVNW DIGITAL TURBINE
AIN AVIAT NETWORKS
CMCO ALBANY INTERNATIONAL CORP. CLASS A
ENPH COLUMBUS MCKINNON CORPORATION
HTLD ENPHASE ENERGY INC.
SACH HEARTLAND EXPRESS INC.
DMLP SACHEM CAPITAL
HLNE DORCHESTER MINERALS L.P.
ANGI HAMILTON LANE INCORPORATED CLASS A
MBIN ANGI INC. CLASS A
LILA MERCHANTS BANCORP
FF LIBERTY LATIN AMERICA A
MEC FIRST MINING GOLD
NOVA MAYVILLE ENGINEERING
GRWG SUNNOVA ENERGY INTERNATIONAL
PCB GROWGENERATION
CLDX PACIFIC CITY FINANCIAL CORP
FBRX CELLDEX THERAPEUTICS INC.
TFC FORTE BIOSCIENCES INC
ONEW TRUIST FINANCIAL CORP
ARRY ONEWATER MARINE
SSSS ARRAY TECHNOLOGIES
ABCL SUTTER ROCK CAPITAL CORP.
CSU ABCELLERA BIOLOGICS
IMNM CAPITAL SENIOR LIVING
GRNT IMMUNOME
PFBX GRANIT SKOPKE
TRIN PEOPLES FINANCIAL CORP. (MISSISSIPPI)
ZETA TRINITY CAPITAL INC
RWAY ZETA GLOBAL HLDGS CORP
ANTX RUNWAY GROWTH FINANCE CORP
NXGL AN2 THERAPEUTICS INC
CALC NEXGEL INC
DBD CALCIMEDICA INC.
CATX DIEBOLD NIXDORF INCORPORATED
MDRR PERSPECTIVE THERAPEUTICS
PDYN INC.
DC MEDALIST DIVERSIFIED REIT INC.
AGFY SARCOS TECHNOLOGY AND ROBOTICS CORP
ETS DAKOTA GOLD CORP.
AGRIFY CORPORATION
ENTERASYS NETWORKS INC /DE/

Tenet Healthcare Corporation: Update to credit analysis following upgr...

Our credit view of this issuer reflects its considerable scale and its very good liquidity and favorable debt maturity profile, offset by its moderately high financial leverage.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch